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Cancer chemotherapy is administered every day to 
numerous cancer patients, with neutropenia mostly a 
normally expected event [1,2]. During neutropenia, 
bacterial sepsis remains a major threat [3]. Potential 
sources of infection include primarily the lungs, the 
digestive tract, and the bloodstream [4,5]. Some of the 
patients with prolonged neutropenia are more likely to 
present with nonbacterial infections, namely acute 
leukemia patients and stem cell/bone marrow transplant 
recipients [6]. Although neutrophils are believed to have 
a pivotal role in the pathophysiology of acute lung injury 
(ALI) and acute respiratory distress syndrome (ARDS), 
early evidence emerged that neutropenic patients were 
not spared from ALI and ARDS [7]. Several hypotheses 
have been raised, including alveolar macrophage or 
monocyte deactivation [8] in relation to malignancy, 
cancer chemotherapy or sepsis.
Neutropenia recovery occurs silently in the vast 
majority of patients. Deterioration of the respiratory 
status, however, has been reported during resolution of 
leukopenia [9,10] – that is, 2 to 3 days before and after 
the neutrophil count reaches 500/mm3 or the leukocyte 
count reaches 1,000/mm3 [11]. An aggravating role of 
granulocyte colony-stimulating factor (G-CSF) has been 
suggested in both clinical and experimental ﬁ  ndings 
[12,13]. Patients at risk for ALI/ARDS during neutropenia 
recovery are those with pulmonary inﬁ  ltrates  during 
neutropenia [10,12,13]. Other risk factors that have been 
suggested include delayed or pro  longed neutropenia [10] 
and invasive pulmonary aspergillosis [14].
In the previous issue of Critical Care, Rhee and 
coworkers assessed the risk factors for ARDS in 71 
critically ill patients with hematologic malignancies and 
long-lasting neutropenia [1]. All of the patients received 
G-CSF. About one-half of the patients developed ARDS 
during neutropenia recovery. Th   e authors identiﬁ  ed that 
patients presenting pneumonia during neutropenia were 
at higher risk of ARDS during neutropenia recovery.
Th  e present study provides additional evidence that 
neutropenic patients presenting clinically or microbio-
logically documented pneumonia should be monitored 
carefully at the time of neutropenia recovery. Th  e  study 
also raises the issue of G-CSF-related pulmonary toxicity 
in this context [15]. Th  ere are, however, three potential 
sources of bias in the study that should be highlighted.
First, one-half of the patients had an acute leukemia, all 
of them receiving G-CSF. Although the safety of G-CSF 
in patients with acute leukemia has been well established 
in numerous clinical trials, its potential advantages 
remain inconclusive since there is no evidence of a 
reduction in the overall frequency of infectious compli-
cations or the duration of hospitalization, nor any beneﬁ  t 
in terms of disease-free survival or overall survival [16]. 
Th  e  beneﬁ  t–risk ratio of G-CSF in these patients should 
therefore be carefully addressed in each individual case.
Second, the neutropenia duration was rather long in 
the present study (22.5 days), which is in agreement with 
the fact that 90% of the patients received chemotherapy 
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© 2010 BioMed Central Ltdfor acute leukemia. Prolonged neutropenia has been 
identiﬁ  ed as a risk factor for respiratory deterioration 
during neutropenia recovery [10]. Th   is also indicates that 
the 50% incidence and the severity of respiratory 
deteriora  tion during neutropenia recovery reported in 
Rhee and colleagues’ study may not be generalizable to all 
patients with hematological malignancies such as diﬀ  use 
B-cell lymphoma or myeloma, and even less to patients 
with solid tumors.
Th   ird, the mortality rate reported in the study is in the 
higher ranges of recently published data [17,18]. Th  is  is 
probably further proof that patients reported in the 
paper by Rhee and coworkers are among the sickest 
critically ill leukemic patients. Along this line, the 
absence of docu  mented invasive aspergillosis in the 
study is a surprising ﬁ  nding.
Although no sound causal relationship can be estab-
lished from these data between neutropenia recovery and 
ARDS, we would like to emphasize the ﬁ  ve convincing 
arguments supporting the reality of ARDS during 
neutropenia that the authors developed in their 
discussion section. First, a high proportion of patients in 
whom neutropenia had been complicated by pneumonia 
will present with substantial respiratory deterioration 
during neutropenia recovery. Also, the incidence of ALI/
ARDS in neutropenic patients with pneumonia is far 
higher during than before or after neutropenia recovery. 
Th  ird, several groups from diﬀ  erent parts of the world 
have described this clinical entity. Further, the experi-
mental models of ALI/ARDS in neutropenic rats have 
been able to reproduce this condition with reasonable 
pathophysiology hypotheses. Finally, this ARDS situation 
is clinically plausible in these frail lung’s patients with 
established predisposition to infections [19], cancer 
chemotherapy and G-CSF-induced pulmonary toxicity, and 
sometimes to pulmonary inﬁ  ltration by the malignancy.
In the future, early recognition of those patients likely 
to present ALI/ARDS in this speciﬁ  c clinical setting is a 
worthwhile endeavor. Th   e relevance of routine screening 
for each individual patient’s risk factors is made crucial 
by the fact that the ﬁ  rst symptoms of ARDS may occur 
before biological leukocyte recovery, and by the need to 
weight the beneﬁ  t–risk ratio of G-CSF administration in 
every patient with clinically or microbiologically 
pneumonia compli  cating neutropenia.
Abbreviations
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